

# Progesterone and Progestins

---

## Selected References:

- Carmichael SL, et al. 2005. Maternal progestin intake and risk of hypospadias. *Archives of Pediatrics & Adolescent Medicine*, 159(10):957-962.
- Check JH, et al. 1986. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. *Fertil Steril*, 45:575-577.
- Committee on Drugs. 2001. The transfer of drugs and other chemicals into human milk. *Pediatrics*, 108(3):776-789.
- American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. 2021. rPrediction and prevention of spontaneous preterm birth: ACOG Practice Bulletin, Number 234. *Obstet Gynecol*, 138(2):e65-e90.
- Devall AJ, et al. 2021. Progestogens for preventing miscarriage: A network meta-analysis. *Cochrane Database Sys Rev*, 4(4):CD013792.
- Duds I, et al. 2006. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. *Congenit Anom (Kyoto)*, 46:194-198.
- Fawzy M, et al. 2008. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. *Arch Gynecol Obstet*, 278(1):33-38.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy. Littleton, Mass.: John Wright-PSG, pp 389, 391-392, 394, 443, 478, 497.
- Heinonen OP, et al. 1977. Cardiovascular birth defects and antenatal exposure to female sex hormones. *N Engl J Med*, 296:67-60.
- Massai R, et al. 2005. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. *Contraception*, 72:352-357.
- Michaelis J, et al. 1983. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. *Teratology*, 27:57-64.
- Norman JE, et al. 2009. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. *Lancet*, 373(9680):2034-2040.
- Practice Committee of the American Society for Reproductive Medicine. 2008. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. *Fertility and Sterility*, 89(4):789-792.
- Practice Committee of the American Society for Reproductive Medicine. 2012. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertility and Sterility*, 98(5):1103-1111.
- RamaRao S, et al. 2013. Progesterone vaginal ring: Introducing a contraceptive to meet the needs of breastfeeding women. *Contraception*, 88(5):591-598.
- Roy M, et al. 2020. Progesterone vaginal ring as a new contraceptive option for lactating mothers: Evidence from a multicenter non-randomized comparative clinical trial in India. *Contraception*, 102(3):159-167.
- Silver RI, et al. 1999. In vitro fertilization is associated with an increased risk of hypospadias. *J Urology*, 161(6):1954-1957.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

## Progesterone and Progestins

### Selected References:

- Aase JM, et al. 1970. Children of mothers who took LSD in pregnancy. *Lancet* 1:100-1.
- Baquiran M, et al. 2023. Lysergic acid diethylamide toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553216/>
- Cohen MM, et al. 1968. The effect of LSD-25 on the chromosomes of children exposed in utero. *Pediat Res* 2:486-492.
- Das, Saibal et al. Lysergic acid diethylamide: a drug of 'use'?. *Therapeutic advances in psychopharmacology* 6,3 (2016): 214-28.
- Fabro S, Sieber SM. 1968. Is lysergide a teratogen? *Lancet* 1(7543):639.
- Fuentes, Juan & Fonseca, Francina & Elices, Matilde & Farré, Magí & Torrens, Marta. (2020). Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. *Frontiers in Psychiatry*. 10. 943. 10.3389/fpsy.2019.00943.
- Jacobson CB, Berlin CM. 1972. Possible reproductive detriment in LSD users. *JAMA* 222(11):1367-1373.
- Haden, M, & Woods, B. 2020. LSD overdoses: three case reports. *Journal of Studies on Alcohol and Drugs*, 81(1), 115-118.
- Long SY. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. *Teratology* 6(1):75-90.
- McElhatton PR. 2000. Fetal effects of substances of abuse. *J Toxicol Clin Toxicol*; 38:194-5.
- McGlothlin WH, et al. 1970. Effect of LSD on human pregnancy. *JAMA*. 1; 212(9):1483-7.
- Mueller, B. A., Daling, J. R., Weiss, N. S., & Moore, D. E. (1990). Recreational drug use and the risk of primary infertility. *Epidemiology (Cambridge, Mass.)*, 1(3), 195-200
- Papac DI and Foltz RL. 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. *J Anal Toxicol*. 14(3):189-90.
- Robinson JT, et al. 1974. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. *J Psychiatry*. 125(0):238-44

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

# Progesterone and Progestins

## Selected References

- Bristol-Myers Squibb. 2019. Available at <https://clinicaltrials.gov/ct2/show/record/NCT01087125?view=record>
- Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). *BioDrugs*, 37(1):73-87.
- E.R. Squibb and Sons, L.L.C. (Last updated: October 30, 2023). Orenzia drug label. Source: National Library of Medicine. Available at <https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb>.
- Ghalandari N, et al. 2022. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. *Br J Clin Pharmacol*, 88(12):5378-5388.
- Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. *Semin Arthritis Rheum*, 45(3):351-356.
- Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. *Drugs*, 71(15):1973-1987.
- National Institutes of Health. (Last updated February 24, 2024). COVID-19 Treatment Guidelines: Abatacept. Available at <https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/abatacept/> through August 16, 2024.
- Ojeda-Uribe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. *Clin Rheumatol*, 32(5):695-700.
- Ostensen M and Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. *Curr Opin Rheumatol*, 23(3):293-298.
- Partlett R and Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. *Rheumatol Int*, 31(4):445-449.
- Pham T., et al. 2012. Abatacept therapy and safety management. *Joint Bone Spine*, 79 Suppl 1:3-84.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

## Progesterone and Progestins

### Selected References:

- Ali, R, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC gastroenterology*; 22.1: 1-10.
- Anderka M, et al. 2012. National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. *Birth Defects Res A Clin Mol Teratol*; 94:22-30.
- Andersen ABT, et al. 2012. Prenatal exposure to acid-suppressive drugs and the risk of toddler asthma: a population-based Danish cohort study. *Alim Pharmacol Ther*; 35:1190-1198.
- Anderson P. 2018. Treating gastroesophageal reflux and heartburn while breastfeeding. *Breastfeed Med*;13(7):463-4.
- Bank, T, et al. 2024. Challenges in Conducting Clinical Trials for Preeclampsia. *Curr Hypertens Rep* 26, 59-68.
- Bor S, et al. 2017. The levels of pantoprazole in human breast milk and plasma: two compartment model. *Neurogastroenterol Motil*; 29:79-80.
- Dehlink E, et al. 2009. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. *Clin Exp Allergy* 39:246-53.
- Diav-Citrin O, et al. 2005. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. *Aliment Pharmacol Ther*; 21:269-75.
- Erichsen R, et al. 2014. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. *Am J Ther*; 21: 254-259.
- Gill SK et al. 2009. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. *Am J Gastroenterol*; 104(6): 1541-1545.
- Hastie R, et al. 2019. Proton pump inhibitors and preeclampsia risk among 157 720 women: a Swedish population register-based cohort study. *Hypertension*; 73(5):1097-103.
- Huijgen NA. 2016. Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy? *Fertility and Sterility*, 106(7), 1666-1672.
- Kallen B. 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Br J Obstet Gynaecol*; 105:877-881.
- Kallen B. 2001. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during pregnancy. *Eur J Obstet Gynecol Reprod Biol*; 96:63-68.
- Keihani, S. et al. 2018. Proton-pump inhibitor use does not affect semen quality in subfertile men. *Asian journal of andrology*, 20(3), 290.
- Lalkin A, et al. 1998. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. *Am J Obstet Gynecol*; 179(3 Pt 1): 727-730.
- Li, C, et al. 2020. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. *Alimentary pharmacology & therapeutics*; 51.4: 410-420.

- Mahadevan, Uma. 2007. "Gastrointestinal Medications in Pregnancy." Best Practice & Research Clinical Gastroenterology 21(5): 849-77.
- Majithia, R., & Johnson, D. A. (2012). Are Proton Pump Inhibitors Safe during Pregnancy and Lactation? 10.
- Marshall JK, et al. 1998. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol; 12: 225-227.
- Matok I, et al. 2012. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci; 57:699-705.
- Mumtaz, N, et al. Harmful Consequences of Proton Pump Inhibitors on Male Fertility: An Evidence from Subchronic Toxicity Study of Esomeprazole and Lansoprazole in Wistar Rats. International Journal of Endocrinology.
- Nikfar S, et al. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci; 47:1526-9.
- Neuman R, et al. 2022. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1). Hypertension, vol. 79,6: 1297-1307.
- Pasternak B, Hviid A. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med; 363:2114-2123.
- Saito J, et al. 2020. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. Breastfeeding Medicine, bfm.2020.0175.
- Thélin CS, & Richter JE. 2020. Review article: the management of heartburn during pregnancy and lactation. Alimentary Pharmacology & Therapeutics, 51(4), 421-434.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. J Clinic Pharmacol; 56: 116-123

[¿Preguntas? Llame al 866.626.6847](#) | [Texto 855.999.3525](#) | [Correo electrónico o chat en MotherToBaby.org](#) .

---

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.

# Progesterone and Progestins

---

## Selected References:

- Affendi Raja RA, et al. 2022. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. *BMC Gastroenterology*, 22:219-229.
- Courtney TP, et al. 1988. Excretion of famotidine in breast milk. *Br J Clin Pharmacol*, 626:639P.
- Garbis H, et al. 2005. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. *Reprod Toxicol*, 19:453-458.
- Hagemann, TM, 1998. Gastrointestinal medications and breastfeeding. *Journal of Human Lactation*, 14(3):259-262.
- Kallen B, 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Journal of Obstetrics and Gynecology*, 105:877-881.
- Magee LA, et al. 1996. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. *Dig Dis Sci*, 41(6):1145-1149.
- Matok I, et al. 2010. The safety of H (2)-blockers use during pregnancy. *J Clin Pharmacol*, 50(1):81-87.
- Orenstein SR, Shalaby TM, Devandry SN, et al. 2003. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. *Aliment Pharmacol Ther*, 7(9):1097-107.
- Savarino V, et al. 1988. Famotidine has no significant effect on gonadal function in man. *Gastroenterol Clin Biol*, 12:19-22.
- Wang X, et al. 2011. Pharmacokinetics of famotidine in pregnant women. *Am J Obstet Gynecol.*, 204: 72-73.
- Yitshak-Sade M, et al. 2016. Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring. *J Clin Pharmacol*, 56(1):116-123.

[¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org](#) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de mayo de 2024.